
|Videos|November 13, 2021
Jelmyto a “paradigm shift” in treating upper tract urothelial carcinoma
Author(s)Urology Times staff
“What's great about [Jelmyto] is you can avoid a pretty morbid operation in a typically unhealthy older population, and treat them with localized therapy,” says Jason M. Hafron, MD.
Advertisement
In a video interview conducted at the 2021 LUGPA annual meeting, Jason M. Hafron, MD, discusses his experience with mitomycin-containing reverse thermal gel (Jelmyto) in the treatment of low-grade upper tract urothelial cancer. Hafron is a partner at the Michigan Institute of Urology, PC; an associate professor of urology at the William Beaumont School of Medicine, Oakland University; and the director of robotic surgery at Beaumont Hospital Royal Oak in Michigan.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Datopotamab deruxtecan enters phase 3 trial in high-risk muscle-invasive urothelial cancer
2
Nicole L. Miller, MD, FACS, on persistent LUTS after BPH treatment
3
Initial prostate cancer presentation, family history linked to survival in mCRPC
4
AI system links surgical gestures with postoperative outcomes
5












